JRP
ACAD icon

Jasper Ridge Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Jasper Ridge Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-20,517
Closed -$564K – 116
2013
Q3 		$564K Buy
+20,517
New +$429K 0.03% 82

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jasper Ridge Partners's ACAD Position: Q4 2013 in Review

Jasper Ridge Partners sold out of Acadia Pharmaceuticals (ACAD) in Q4 2013, closing a stake of 20,517 shares — an estimated $564K sold.

Jasper Ridge Partners first reported a position in ACAD in Q3 2013 and held it in 1 quarter. The position peaked at $564K in Q3 2013. 155 funds tracked by Wall St. Rank hold ACAD as of Q4 2013.

  • Jasper Ridge Partners reported no remaining Acadia Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Jasper Ridge Partners sold 20,517 Acadia Pharmaceuticals shares in Q4 2013, an estimated $564K.
  • Jasper Ridge Partners first reported a position in Acadia Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Jasper Ridge Partners's Acadia Pharmaceuticals position peaked at $564K in Q3 2013.
  • 155 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2013.

Based on Jasper Ridge Partners's 13F filing for Q4 2013, filed 7 Feb 2014.